| 刊名 | Medicinal Plant |
| 作者 | Zhixia WANG |
| 作者单位 | School of Pharmacy,Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University),Ministry of Education,Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong,Yantai University,Yantai |
| DOI | 10.19601/j.cnki.issn2152-3924.2024.06.001 |
| 年份 | 2024 |
| 刊期 | 6 |
| 页码 | 1-6 |
| 关键词 | Tumor,Doxorubicin hydrochloride liposomes,Targeted therapy,Protopanaxadiol,Clinical requirement |
| 摘要 | [Objectives]To prepare protopanaxadiol type doxorubicin hydrochloride liposomes by replacing cholesterol with protopanaxadiol,a derivative of ginsenoside,which has a similar structure with cholesterol,to reduce the adverse reaction of adriamycin (doxorubicin) and improve the shortcomings of ordinary doxorubicin hydrochloride.[Methods]Liposomes were prepared by thin film dispersion-ammonium sulfate gradient method,and the optimal formulation was screened by Box-Behnken experiment with particle size and encapsulation efficiency as the evaluation indicator through single factor experiment,and the drug release in vitro was verified.[Results]The average particle size of the liposomes was (149.21±1.2) nm,the polydispersity index (PDI) was (0.22±0.02),and the potential was-(15.22±1.57) mV.The liposomes were spherical and uniform in size; the encapsulation efficiency and drug loading of the new doxorubicin hydrochloride liposomes were (89.71±4.4)% and (7.28±0.8)%,respectively.[Conclusions]The new doxorubicin hydrochloride liposomes was successfully prepared by a film dispersion-ammonium sulfate gradient method,the internal circulation of the doxorubicin hydrochloride liposomes was prolonged,and the new material has good stability.This study is expected to lay a foundation for the successful preparation of new doxorubicin hydrochloride liposomes in vitro and in vivo. |
